CAMBRIDGE, Mass.--(BUSINESS WIRE)--GnuBIO, Inc. (GnuBIO), www.gnubio.com a pioneer in the Desktop DNA sequencing market, announced today that it has shipped an Early Access system to the Université de Montréal Pharmacogenomics Centre at the Montreal Heart Institute, where the system was used to accurately sequence a blinded cohort of clinical cardiomyopathy samples. The GnuBIO system will allow researchers and clinicians to sequence patients cost effectively on a per sample basis, thus obviating the need to batch samples. Furthermore, the system will have the ability to provide clinicians with genetic results within a couple of hours, as opposed to weeks.
